StockData
GT Biopharma, Inc. logo

GT Biopharma, Inc. (GTBP) stock

GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 5/30
$3.18−0.35 (-10.04%)

Close on Nov 17, 2026Market cap $143.45MP/E –Yield –

GT Biopharma enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

GT Biopharma's enterprise value was $94.05M on Nov 11, 2026, against $117.01M a year earlier. Over the last 5 years it ranged from $42.67M to $2.52B, with a median of $192.18M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$94.05M-19.1%
2025Dec 31, 2025$116.27M-29.0%
2024Dec 31, 2024$163.86M-33.9%
2023Dec 29, 2023$248.07M-65.6%
2022Dec 30, 2022$720.79M+83.7%
2021Dec 31, 2021$392.45M-97.2%
2020Dec 31, 2020$13.97B+506.7%
2019Dec 31, 2019$2.30B-83.4%
2018Dec 31, 2018$13.88B-85.3%
2017Dec 29, 2017$94.14B–

More GT Biopharma figures

See a number that looks wrong?